An evaluation of the AggreGuide A-100 ADP Assay for measuring the effect of antiplatelet agents targeting the P2Y₁₂ receptor

ABSTRACT

Introduction

Currently available platelet function assays largely ignore the important characteristics of in vivo thrombus generation, such as flow conditions and shear. The AggreGuide A−100 ADP Assay detects platelet aggregation in whole blood using light scattering under flow conditions.

Areas covered

In this review article, we discuss the limitations of currently available platelet function assays and the technology underlying the AggreGuide A−100 ADP assay. We also discuss the results of the validation assay study.

Expert Opinion

By incorporating arterial flow conditions and shear, the AggreGuide assay may be more indicative of in vivo thrombus generation as compared to currently available platelet function assays. As per the United States, Food and Drug administration, the AggreGuide A−100 ADP test has been cleared to assess antiplatelet effects of prasugrel and ticagrelor. The assay results are comparable to widely used VerifyNow PRU assay. The utility of AggreGuide A100-ADP Assay in guiding P2Y12 receptor inhibitor therapy in patients with cardiovascular disease needs to be explored in clinical studies.

KEYWORDS:

• platelet aggregation
• Platelet function assay
• AggreGuide A-100 ADP assay
• clopidogrel
• prasugrel
• ticagrelor

Declaration of interest

Dr. Tantry received consultation fees from Aggredyne, Inc and UpToDate. Dr. Ramotowski reports honoraria for lectures from Werfen, GE, Boerhinger Ingelheim. Dr. Gurbel has received consulting fees and/or honoraria from Bayer, Otitopic, Janssen, UpToDate, Cleveland Clinic, Adeno, Wolters Kluwer Pharma, Web MD Medscape, Baron and Budd, North American Thrombosis Forum, Innovative Sciences; institutional research grants from the Haemonetics, Janssen, Bayer, Instrumentation Laboratories, Amgen, Idorsia, Otitopic, Hikari Dx, Novartis, Precision Biologic, Nirmidas Biotech, and R-Pharma International; in addition, Dr. Gurbel has two patents, Detection of restenosis risk in patients issued and Assessment of cardiac health and thrombotic risk in a patient. Dr. Gurbel was an expert witness in a lawsuit associated with Plavix. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewers Disclosure

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.